Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

Chr t(8;21) + KIT mutation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

Chr t(8;21) + KIT mutation	Acute Myelogenous Leukemia	Chr t(8;21) + KIT mutation	Acute Myelogenous Leukemia	venetoclax + midostaurin Sensitive: C3 – Early Trials venetoclax + midostaurin Sensitive : C3	venetoclax + midostaurin Sensitive: C3 – Early Trials venetoclax + midostaurin Sensitive : C3
Chr t(8;21) + KIT mutation	Acute Myelogenous Leukemia	Chr t(8;21) + KIT mutation	Acute Myelogenous Leukemia	venetoclax Resistant: C3 – Early Trials venetoclax Resistant : C3	venetoclax Resistant: C3 – Early Trials venetoclax Resistant : C3
Chr t(8;21) + KIT mutation	Acute Myelogenous Leukemia	Chr t(8;21) + KIT mutation	Acute Myelogenous Leukemia	cytarabine Sensitive: C3 – Early Trials cytarabine Sensitive : C3	cytarabine Sensitive: C3 – Early Trials cytarabine Sensitive : C3
Chr t(8;21) + KIT mutation	Acute Myelogenous Leukemia	Chr t(8;21) + KIT mutation	Acute Myelogenous Leukemia	cabozantinib tablet Sensitive: D – Preclinical cabozantinib tablet Sensitive : D	cabozantinib tablet Sensitive: D – Preclinical cabozantinib tablet Sensitive : D